(NASDAQ: GMAB) Genmab A's forecast annual revenue growth rate of 16.73% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 116.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.07%.
Genmab A's revenue in 2026 is $3,563,740,000.On average, 25 Wall Street analysts forecast GMAB's revenue for 2026 to be $279,104,999,103, with the lowest GMAB revenue forecast at $245,589,284,925, and the highest GMAB revenue forecast at $305,429,602,193. On average, 21 Wall Street analysts forecast GMAB's revenue for 2027 to be $315,638,411,684, with the lowest GMAB revenue forecast at $276,023,094,351, and the highest GMAB revenue forecast at $346,264,840,157.
In 2028, GMAB is forecast to generate $369,058,094,052 in revenue, with the lowest revenue forecast at $327,966,030,692 and the highest revenue forecast at $415,671,903,426.